PMID- 36506550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors 
      in patients with type 2 diabetes mellitus: A system review and network 
      meta-analysis.
PG  - 986186
LID - 10.3389/fphar.2022.986186 [doi]
LID - 986186
AB  - Cardiovascular and renal impairment are the most common complications of type 2 
      diabetes mellitus (T2DM). As an emerging class of glucose-lowing agents sodium 
      glucose co-transporter 2 (SGLT2), possesses beneficial effects on cardiovascular 
      and renal outcomes in patients with T2DM. The aim of this study is to assess the 
      efficacy of different SGLT2 inhibitors for cardiovascular and renal outcomes for 
      patients with T2DM when compared with placebo. We performed a systematic search 
      of PubMed, Embase, and the Cochrane library from inception through November 2021. 
      Randomized clinical trials enrolling participants with T2DM were included, in 
      which SGLT2 inhibitors were compared with each other or placebo. The primary 
      outcomes including all-caused mortality, Cardiovascular outcomes (cardiovascular 
      mortality, hospitalization for heart failure), and the renal composite outcomes 
      (worsening persistent microalbuminuria or macroalbuminuria, new or worsening 
      chronic kidney disease, doubling of serum creatinine, end-stage renal disease, 
      renal transplant, or renal death). The data for the outcomes were pooled and 
      recorded as Hazard rations (HRs) with 95% confidence intervals (CLs). Two 
      researcher independently screened the trials and drawn the data. Ten trials 
      enrolling 68,723 patients were included. Compared with placebo groups, 
      Canagliflozin [HR, 0.85 (95%CI, 0.75-0.98)], ertugliflozin [HR, 0.93 (95%CI, 
      0.78-1.11)], and sotagliflozin [HR, 0.94 (95%CI, 0.79-1.12)] were associated with 
      a reduction in all-cause mortality. Canagliflozin [HR, 0.84 (95%CI, 0.72-0.97)], 
      dapagliflozin [HR, 0.88 (95%CI, 0.79-0.99)], empagliflozin [HR, 0.62 (95%CI, 
      0.49-0.78)], ertugliflozin [HR, 0.92 (95%CI, 0.77-1.10)], and sotagliflozin [HR, 
      0.88 (95%CI, 0.73-1.06)] were associated with a reduction in cardiovascular 
      mortality; Canagliflozin [HR, 0.64 (95%CI, 0.53-0.77)], dapagliflozin [HR, 0.71 
      (95%CI, 0.63-0.81)], empagliflozin [HR, 0.65 (95%CI, 0.50-0.85)], ertugliflozin 
      [HR, 0.70 (95%CI, 0.54-0.90)], and sotagliflozin [HR, 0.66 (95%CI, 0.56-0.77)] 
      were associated with a reduction in hospitalization for heart failure. 
      Dapagliflozin [HR, 0.55 (95%CI, 0.47-0.63)], Empagliflozin [HR, 0.54 (95%CI, 
      0.39-0.74)], canagliflozin [HR, 0.64 (95%CI, 0.54-0.75)], sotagliflozin [HR, 0.71 
      (95%CI, 0.46-1.09)], and ertugliflozin [HR, 0.81 (95%CI, 0.63-1.04)] were 
      associated with a reduction in the renal composite outcome. All SGLT2 inhibitors 
      showed a reduction in cardiovascular mortality, hospitalization for heart 
      failure, renal composite outcomes and all-cause mortality. Canagliflozin and 
      empagliflozin seemed to have the same efficacy in reducing hospitalization for 
      heart failure, but empagliflozin had advantage in reducing cardiovascular 
      mortality, whereas dapagliflozin most likely showed the best renal composite 
      outcomes.
CI  - Copyright (c) 2022 Tian, Ai, zheng, Yang, Zhou, Tang, Liu, Zhao and Wang.
FAU - Tian, Lei
AU  - Tian L
AD  - Department of Nephrology, Beijing Hospital of Traditional Chinese Medicine, 
      Capital Medical University, Beijing, China.
FAU - Ai, Sinan
AU  - Ai S
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Zheng, Huijuan
AU  - Zheng H
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Yang, Hanwen
AU  - Yang H
AD  - China-Japan Friendship Hospital, Beijing, China.
FAU - Zhou, Mengqi
AU  - Zhou M
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Tang, Jingyi
AU  - Tang J
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Liu, Weijing
AU  - Liu W
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Zhao, Wenjing
AU  - Zhao W
AD  - Department of Nephrology, Beijing Hospital of Traditional Chinese Medicine, 
      Capital Medical University, Beijing, China.
FAU - Wang, Yaoxian
AU  - Wang Y
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Key 
      Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, 
      Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 
      Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20221124
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9731650
OTO - NOTNLM
OT  - cardiovascular outcomes
OT  - network meta-analysis
OT  - renal outcomes
OT  - sodium glucose co-transporter 2 (SGLT2) inhibitors
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/13 06:00
MHDA- 2022/12/13 06:01
PMCR- 2022/11/24
CRDT- 2022/12/12 11:18
PHST- 2022/07/04 00:00 [received]
PHST- 2022/11/02 00:00 [accepted]
PHST- 2022/12/12 11:18 [entrez]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2022/12/13 06:01 [medline]
PHST- 2022/11/24 00:00 [pmc-release]
AID - 986186 [pii]
AID - 10.3389/fphar.2022.986186 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Nov 24;13:986186. doi: 10.3389/fphar.2022.986186. 
      eCollection 2022.